Status:
COMPLETED
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Amgen
National Institutes of Health (NIH)
Conditions:
Lymphoma, Non-Hodgkin
Lymphomas: Non-Hodgkin
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Eligibility Criteria
Inclusion
- Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Exclusion
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00398372
Start Date
November 1 2000
End Date
September 1 2009
Last Update
June 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305